Drugs / Gosereline
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05352178 | Apr 2022 → Apr 2027 expected | metastatic malignant neoplasm, metastatic prostate carcinoma | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02175212 Comparator | Nov 2005 → Jun 2014 | prostate adenocarcinoma | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gosereline | “Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or...” NCT05352178 ↗1“Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)” NCT02175212 ↗ |
| Known as | goserelin | “Patients assigned to the short-term androgen deprivation group received 4 months of neoadjuvant and concomitant androgen deprivation with subcutaneous goserelin (2 months...” PMID 25702876 ↗ Feb 2015 |
| Route | Subcutaneous | “10.8 mg by subcutaneous injection” NCT02175212 ↗ |